Formulation and In Vitro Assessment of a Hybrid Gel‐Microparticle Composite for Ocular Delivery of Dual‐Antiglaucoma Drugs
Macromolecular Bioscience · 2025
DOI: 10.1002/mabi.202500270 ↗Kurz gefasst
Fachartikel in der Zeitschrift Macromolecular Bioscience, 2025. Verfasst von Subrat Kumar Panigrahi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemical Engineering, Indian Institute of Technology, Hyderabad, India. Hauptthemen laut MEDLINE: Glaucoma, Timolol, Hydrogels, Latanoprost. Die Arbeit nennt 53 Literaturangaben. Gefördert von: Indian Council of Medical Research, Department of Health Research, Ministry of Health and Family Welfare, India.
Abstract (Originalsprache)
Glaucoma, a major global health issue, is the second leading cause of blindness. Topical eye drops are commonly used due to their simplicity, but the eye's protective barriers hinder optimal drug concentration at the target site. This study addresses these challenges by developing a novel dual‐drug delivery system, integrating polycaprolactone microparticles loaded with latanoprost(hydrophobic) and timolol maleate(hydrophilic) antiglaucoma drugs into a gelatin‐alginate hydrogel matrix. There is a fundamental challenge to combine both drugs in the same delivery system with a controlled release profile. Hydrogel‐microparticles(HMPs) were assessed via in vitro drug‐release and cell culture for biocompatibility with Raman analysis for chemical compatibility and drug diffusivity. Results showed that the hydrogel‐microparticle system has prolonged drug release for up to 32 days. Raman analysis confirmed the chemical compatibility of the formulation components, and in vitro biocompatibility studies demonstrate that the HMPs system is biocompatible and exhibits minimal toxicity to the cells. This novel HMPs system can serve as a flexible, controlled release platform modulating the release profile. Our study highlights that the polymer and drug properties, along with the external matrix, were key factors influencing the drug release behavior of the formulations, and the proposed HMPs system can potentially be considered for glaucoma therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemical Engineering, Indian Institute of Technology, Hyderabad, India.
ORCID-Profile: Subrat Kumar Panigrahi, Saptarshi Majumdar
Förderung
- Indian Council of Medical Research
- Department of Health Research, Ministry of Health and Family Welfare, India
Zitieren
APA
Panigrahi, S. K., Saha, D., Das, S., Majumdar, S., & Giri, L. (2025). Formulation and In Vitro Assessment of a Hybrid Gel‐Microparticle Composite for Ocular Delivery of Dual‐Antiglaucoma Drugs. Macromolecular Bioscience. https://doi.org/10.1002/mabi.202500270
Vancouver
Panigrahi SK, Saha D, Das S, Majumdar S, Giri L. Formulation and In Vitro Assessment of a Hybrid Gel‐Microparticle Composite for Ocular Delivery of Dual‐Antiglaucoma Drugs. Macromolecular Bioscience. 2025. doi:10.1002/mabi.202500270
BibTeX
@article{Panigrahi2025,
author = {Panigrahi, Subrat Kumar and Saha, Debasmita and Das, Sougat and Majumdar, Saptarshi and Giri, Lopamudra},
title = {Formulation and In Vitro Assessment of a Hybrid Gel‐Microparticle Composite for Ocular Delivery of Dual‐Antiglaucoma Drugs},
journal = {Macromolecular Bioscience},
year = {2025},
doi = {10.1002/mabi.202500270}
}
EUVIMED